FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2323320635> ?p ?o ?g. }

• W2323320635 endingPage "e1014" @default.
• W2323320635 startingPage "e1014" @default.
• W2323320635 abstract "The prognosis of advanced gastrointestinal stromal tumors (GISTs) was dramatically improved in the era of imatinib. Cytoreduction surgery was advocated as an additional treatment for advanced GISTs, especially when patients having poor response to imatinib or developing resistance to it. However, the efficacy and benefit of cytoreduction were still controversial. Likewise, the sequence between cytoreduction surgery and imatinib still need evaluation. In this study, we tried to assess the feasibility and efficiency of cytoreduction in advanced GISTs. Furthermore, we analyzed the impact of timing of the cytoreduction surgery on the prognosis of advanced GISTs. We conducted a prospective collecting retrospective review of patients with advanced GISTs (metastatic, unresectable, and recurrent GISTs) treated in Chang Gung memorial hospital (CGMH) since 2001 to 2013. We analyzed the impact of cytoreduction surgery to response to imatinib, progression-free survival (PFS), and overall survival (OS) in patients with advanced GISTs. Moreover, by the timing of cytoreduction to imatinib, we divided the surgical patients who had surgery before imatinib use into early group and those who had surgery after imatinib into late. We compared the clinical response to imatinib, PFS and OS between early and late cytoreduction surgical groups. Totally, 182 patients were enrolled into this study. Seventy-six patients underwent cytoreduction surgery. The demographic characteristics and tumor presentation were similar between surgical and non-surgical groups. The surgical group showed better complete response rate (P < 0.001) and partial response rate (P = 0.008) than non-surgical group. The 1-year, 3-year, and 5-year PFS were significantly superior in surgical group (P = 0.003). The 1-year, 3-year, and 5-year OS were superior in surgical group, but without statistical significance (P = 0.088). Dividing by cytoreduction surgical timing, the demographic characteristics and tumor presentation were comparable in early and late groups. The late cytoreduction group presented higher R0 resection rate (59.1% vs 31.5%, P = 0.025). However, the PFS and OS were comparable in both groups. Combining imatinib with cytoreduction increased the response rate to imatinib and prolonged PFS in patients with advanced GISTs. Moreover, early and late cytoreduction surgery was comparable in prognosis, although late cytoreduction revealed higher complete resection rate." @default.
• W2323320635 created "2016-06-24" @default.
• W2323320635 creator A5001467169 @default.
• W2323320635 creator A5004200993 @default.
• W2323320635 creator A5041485211 @default.
• W2323320635 creator A5048749599 @default.
• W2323320635 creator A5056067944 @default.
• W2323320635 creator A5065151950 @default.
• W2323320635 creator A5082234869 @default.
• W2323320635 creator A5082950787 @default.
• W2323320635 creator A5087399963 @default.
• W2323320635 creator A5090866906 @default.
• W2323320635 creator A5090971578 @default.
• W2323320635 date "2015-06-01" @default.
• W2323320635 modified "2023-10-17" @default.
• W2323320635 title "Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib" @default.
• W2323320635 cites W1540040970 @default.
• W2323320635 cites W1740757994 @default.
• W2323320635 cites W1972914736 @default.
• W2323320635 cites W2012072945 @default.
• W2323320635 cites W2014642132 @default.
• W2323320635 cites W2019607817 @default.
• W2323320635 cites W2034984734 @default.
• W2323320635 cites W2037290765 @default.
• W2323320635 cites W2039631420 @default.
• W2323320635 cites W2055436404 @default.
• W2323320635 cites W2099359513 @default.
• W2323320635 cites W2102012621 @default.
• W2323320635 cites W2115504770 @default.
• W2323320635 cites W2125434194 @default.
• W2323320635 cites W2155741608 @default.
• W2323320635 cites W2169363650 @default.
• W2323320635 cites W2314511842 @default.
• W2323320635 doi "https://doi.org/10.1097/md.0000000000001014" @default.
• W2323320635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4616552" @default.
• W2323320635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26091448" @default.
• W2323320635 hasPublicationYear "2015" @default.
• W2323320635 type Work @default.
• W2323320635 sameAs 2323320635 @default.
• W2323320635 citedByCount "9" @default.
• W2323320635 countsByYear W23233206352016 @default.
• W2323320635 countsByYear W23233206352017 @default.
• W2323320635 countsByYear W23233206352018 @default.
• W2323320635 countsByYear W23233206352019 @default.
• W2323320635 countsByYear W23233206352021 @default.
• W2323320635 countsByYear W23233206352023 @default.
• W2323320635 crossrefType "journal-article" @default.
• W2323320635 hasAuthorship W2323320635A5001467169 @default.
• W2323320635 hasAuthorship W2323320635A5004200993 @default.
• W2323320635 hasAuthorship W2323320635A5041485211 @default.
• W2323320635 hasAuthorship W2323320635A5048749599 @default.
• W2323320635 hasAuthorship W2323320635A5056067944 @default.
• W2323320635 hasAuthorship W2323320635A5065151950 @default.
• W2323320635 hasAuthorship W2323320635A5082234869 @default.
• W2323320635 hasAuthorship W2323320635A5082950787 @default.
• W2323320635 hasAuthorship W2323320635A5087399963 @default.
• W2323320635 hasAuthorship W2323320635A5090866906 @default.
• W2323320635 hasAuthorship W2323320635A5090971578 @default.
• W2323320635 hasBestOaLocation W23233206351 @default.
• W2323320635 hasConcept C126322002 @default.
• W2323320635 hasConcept C141071460 @default.
• W2323320635 hasConcept C143998085 @default.
• W2323320635 hasConcept C167135981 @default.
• W2323320635 hasConcept C16930146 @default.
• W2323320635 hasConcept C2775922572 @default.
• W2323320635 hasConcept C2777583451 @default.
• W2323320635 hasConcept C2778729363 @default.
• W2323320635 hasConcept C3019892230 @default.
• W2323320635 hasConcept C71924100 @default.
• W2323320635 hasConceptScore W2323320635C126322002 @default.
• W2323320635 hasConceptScore W2323320635C141071460 @default.
• W2323320635 hasConceptScore W2323320635C143998085 @default.
• W2323320635 hasConceptScore W2323320635C167135981 @default.
• W2323320635 hasConceptScore W2323320635C16930146 @default.
• W2323320635 hasConceptScore W2323320635C2775922572 @default.
• W2323320635 hasConceptScore W2323320635C2777583451 @default.
• W2323320635 hasConceptScore W2323320635C2778729363 @default.
• W2323320635 hasConceptScore W2323320635C3019892230 @default.
• W2323320635 hasConceptScore W2323320635C71924100 @default.
• W2323320635 hasIssue "24" @default.
• W2323320635 hasLocation W23233206351 @default.
• W2323320635 hasLocation W23233206352 @default.
• W2323320635 hasLocation W23233206353 @default.
• W2323320635 hasOpenAccess W2323320635 @default.
• W2323320635 hasPrimaryLocation W23233206351 @default.
• W2323320635 hasRelatedWork W2047986520 @default.
• W2323320635 hasRelatedWork W2079642245 @default.
• W2323320635 hasRelatedWork W225949814 @default.
• W2323320635 hasRelatedWork W2367850073 @default.
• W2323320635 hasRelatedWork W3012123661 @default.
• W2323320635 hasRelatedWork W3030442802 @default.
• W2323320635 hasRelatedWork W3031477817 @default.
• W2323320635 hasRelatedWork W3117440509 @default.
• W2323320635 hasRelatedWork W4232531420 @default.
• W2323320635 hasRelatedWork W3127233814 @default.
• W2323320635 hasVolume "94" @default.
• W2323320635 isParatext "false" @default.
• W2323320635 isRetracted "false" @default.

• next